Jonathan Young - 15 Jul 2021 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: Chief Operating Officer
Signature: /s/ Jonathan Young
Issuer symbol: AKRO
Transactions as of: 15 Jul 2021
Net transactions value: +$5,535
Form type: 4
Filing time: 19 Jul 2021, 16:43:09 UTC
Previous filing: 02 Jun 2021
Next filing: 03 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Options Exercise	$5,535	+9,000	+5.5%	$0.6150^*	173,010	15 Jul 2021	Direct
holding	AKRO	Common Stock						20,000	15 Jul 2021	By EA Irrevocable Trust	F1
holding	AKRO	Common Stock						20,000	15 Jul 2021	By CM Irrevocable Trust	F1
holding	AKRO	Common Stock						20,000	15 Jul 2021	By JL Irrevocable Trust	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKRO	Employee Stock Option (Right to Buy)	Options Exercise	$0	-9,000	-25%	$0.000000	26,296	15 Jul 2021	Common Stock	9,000	$0.6150	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2	25% of this option vested on August 1, 2018 and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter.